Lucideon has signed an exclusive feasibility, development and licence agreement with a subsidiary of oral and inhalation drug development company Skyepharma.

Under the agreement, Skyepharma’s oral business will have access to Lucideon’s proprietary iCRT-deter abuse deterrent controlled release technology.

iCRT-deter is a drug delivery technology part of Lucideon’s inorganic controlled release platforms.

The technology has been designed in a way that makes drugs difficult to tamper with by several methods including chewing, heating and crushing, while maintaining the necessary controlled release properties.

" … This project is an excellent example of how we work with industry to maximise the properties of materials to meet their technical and commercial needs."

Lucideon healthcare business manager Gemma Budd said: "With features such as an extremely high melting point, and a highly porous particulate structure that maintains the controlled release and abuse deterrent features even when crushed, we believe that iCRT-deter will play a pivotal role in deterring abuse of multiple prescription drugs in the future, a technological advancement that benefits not only patients and providers, but society as a whole.

"The iCRT technology platform has other pharmaceutical applications outside of abuse-deterrence, but this project is an excellent example of how we work with industry to maximise the properties of materials to meet their technical and commercial needs."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lucideon will collaborate with Skyepharma’s oral business in order to evaluate the feasibility of using the technology with an aim to create an abuse deterrent formulation of a major opioid for the US market.

After the success of the feasibility stage, Skyepharma will produce the product as a generic for the US market.

iCRT-deter has been developed as a result of the rising prescription drug abuse problem in many areas across the globe.

In the US, where drug abuse problem is recognised as an epidemic, the Food and Drug Administration (FDA) has proposed an action plan that includes the development of abuse-deterrent formulations of opioid products.